Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
P/E ratio for Torrent Pharmaceuticals Limited (TORNTPHARM.NS)
P/E ratio as of 2023: 54.66
According to Torrent Pharmaceuticals Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 54.66. At the end of 2022 the company had a P/E ratio of 41.78.
P/E ratio history for Torrent Pharmaceuticals Limited from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 54.66 |
| 2022 | 41.78 |
| 2021 | 60.79 |
| 2020 | 34.40 |
| 2019 | 32.56 |
| 2018 | 73.69 |
| 2017 | 31.60 |
| 2016 | 28.14 |
| 2015 | 13.17 |
| 2014 | 26.11 |
| 2013 | 13.36 |
| 2012 | 13.32 |
| 2011 | 18.78 |
| 2010 | 18.18 |
| 2009 | 19.96 |
| 2008 | 6.15 |
| 2007 | 8.85 |
| 2006 | 17.72 |
| 2005 | 36.12 |
| 2004 | 19.21 |